Matinas BioPharma Initiates Dosing in Phase 1 Study of Potential First Oral Aminoglycoside Antibiotic Drug MAT2501

MAT2501 is being developed to potentially become the first oral aminoglycoside, with the application of Matinas proprietary LNC platform technology to the broad-spectrum antibiotic drug amikacin.